Bone Reinforcement

Bone Reinforcement

location_on 西北 ,  瑞士

请注意:
投资于早期阶段的企业存在风险,包括流动性不足、无分红、投资损失及股权稀释等。因此,此类投资应仅作为多元化投资组合的一部分进行。本平台仅面向具备足够专业知识、能够理解相关风险并自行作出投资决策的投资者。我们鼓励投资者自行审阅与评估各项投资,并根据自身判断决定是否参与。本网站所提供的信息仅供参考,我们无法保证其准确性或完整性。我们强烈建议投资者在进行任何投资前,与持牌专业人士完成尽职调查。本平台不提供任何法律或税务方面的建议。

简要概述

NX-Spine is advancing bone enhancement to improve spinal fusion outcomes with a cost-effective platform technology that rapidly reinforces bone to optimize screw stability. Efficacy is equivalent to PMMA but is faster and safer.

亮点

  • Our system has been successfully used in European clinical trials
  • Surgeons and strategics all acknowledge the risk of pedicle screw loosening
  • Other applications are promising: pediatric scoliosis.
  • The FDA supports the pathway, the predicate device, and the study.
  • Strong IP and FTO successfully executed removing risk from US launch.

概览

目标 HK$ 59,000,000
最低标准。 HK$ 1,000,000
融资已到位。 HK$ 9,800,000
过往融资轮次 HK$ 49,000,000
阶段 最简可行产品/成品
投资人角色 任何。

提出一个问题。
有問題嗎?

相似项目

Entac Medical Inc.

Entac Medical Inc.

location_on东南, 美国

Entac develops AI-driven acoustic wearables predicting patient adverse events, with its first launched device, PrevisEA, targeting an $8 billion market and a pipeline for multiple high-value healthcare sectors exceeding $20 billion.

  • PrevisEA Commitments: 5 hospitals systems (63 hospitals) $41M revenue oppy
  • In review: 6 systems (71 hospitals) - $39M opportunity. Commitment due
  • Engaged: 7 systems (120 hospitals) - $67M opportunity - Expected in 2025.

HK$16,000,000

融资目标

HK$400,000

最低投资额
Reducing Heart Attacks

Reducing Heart Attacks

location_on苏黎世, 瑞士

HeartForce’s patented technology allows doctors to place a handheld, non-invasive device on a patient’s chest. It monitors ECG output and assesses arterial blockages. This precise and cost-effective tool could save countless lives.

  • Patented technology that will help to reduce the mortality rate
  • Non-invasive and much more cost effective than any other method
  • HeartForce’s first mover advantage implies there is no direct competition

HK$127,000,000

融资目标

HK$500,000

最低投资额
Loading…
Loading the web debug toolbar…
Attempt #